Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani

Chaubey, Pramila; Mishra, Brahmeshwar; Mudavath, Shyam Lal; Patel, Ravi R.; Chaurasia, Sundeep; Sundar, Shyam; Suvarna, Vasanti; Monteiro, Marvis

doi:10.1016/j.ijbiomac.2017.12.143

Cited by 67 publications

(37 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported the antileishmanial activity of Cur, which is presumably mediated through programmed cell death [ 57 , 58 ]. Cur-loaded mannose-functionalized chitosan nanoparticles (Cur-MCN) have been prepared by mannose-conjugated chitosan to better target macrophages in visceral leishmaniasis [ 59 ]. This formulation was not cytotoxic for J774A.1 cell line.…”

Section: Chitosan-based Drug Loaded Formulations For the Chemothermentioning

confidence: 99%

See 1 more Smart Citation

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis

2020

View full text Add to dashboard Cite

The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite Leishmania, requires continuous innovation at the therapeutic and vaccination levels. Chitosan is a biocompatible polymer administrable via different routes and possessing numerous qualities to be used in the antileishmanial strategies. This review presents recent progress in chitosan research for antileishmanial applications. First data on the mechanism of action of chitosan revealed an optimal in vitro intrinsic activity at acidic pH, high-molecular-weight chitosan being the most efficient form, with an uptake by pinocytosis and an accumulation in the parasitophorous vacuole of Leishmania-infected macrophages. In addition, the immunomodulatory effect of chitosan is an added value both for the treatment of leishmaniasis and the development of innovative vaccines. The advances in chitosan chemistry allows pharmacomodulation on amine groups opening various opportunities for new polymers of different size, and physico-chemical properties adapted to the chosen routes of administration. Different formulations have been studied in experimental leishmaniasis models to cure visceral and cutaneous leishmaniasis, and chitosan can act as a booster through drug combinations with classical drugs, such as amphotericin B. The various architectural possibilities given by chitosan chemistry and pharmaceutical technology pave the way for promising further developments.

show abstract

Section: Chitosan-based Drug Loaded Formulations For the Chemothermentioning

confidence: 99%

“…This formulation was not cytotoxic for J774A.1 cell line. When evaluated in vivo in a L. donovani -infected hamster model, it had the capacity to reduce the spleen parasite burden to a greater extent than unconjugated chitosan nanoparticles [ 59 ].…”

Section: Chitosan-based Drug Loaded Formulations For the Chemothermentioning

confidence: 99%

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis

2020

View full text Add to dashboard Cite

show abstract

“…Polyester NPs for delivery of AmpB delivered by oral route have shown significantly more activity in bone marrow-derived macrophages infected with L. donovani than the AmpB [50]. Moreover, several in vitro and in vivo studies have used rifampicin, doxorubicin, antimony, curcumin and andrographolide-tagged NPs for macrophages-specific receptor delivery, which have shown better antileishmanial activity in comparison with their respective NP nontagged drug-treated groups [51][52][53][54][55][56] and are summarized in Table 2.…”

Section: Nanoparticle-based Drug Delivery System For Vlmentioning

confidence: 99%

“…Chitosan particles conjugated with mannose and rifampicin have shown significant effect for VL treatment [51]. Mannosylated chitosan NPs-loaded curcumin has showed significant uptake by macrophages by endocytosis [56]. Intravenous admiration of resiquimod in polymer microparticles formed by electron spray in mice has shown significant reduction in L. donovani load [57].…”

Section: Nanoparticle-based Drug Delivery System For Vlmentioning

confidence: 99%

Envisioning the Innovations in Nanomedicine to Combat Visceral Leishmaniasis: For Future Theranostic Application

Singh

Gedda

Mudavath

et al. 2019

Nanomedicine (Lond.)

Self Cite

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) is a life-threatening parasitic disease affecting impoverished people of the developing world; and much effort has been spent on the early case detection and treatment. However, current diagnostics and treatment options are not sufficient for appropriate surveillance in VL elimination setting. Hence, there is a dire need to develop highly sensitive diagnostics and less toxic effective treatments for proper management of cases and to achieve the sustained disease elimination. Although, promising results have been observed with nanomedicines in leishmaniasis; there are great challenges ahead especially in translating this to clinical setting. This review provides updated progress of nanomedicines in VL, and discussed how these innovations and future directions play vital role in achieving VL elimination.

show abstract

“…Moreover, it is useful in overcoming challenges such as low solubility, low permeability, high toxicity, and degradation of conventional drugs. Several studies have described the use of various nanocarriers for the treatment of leishmaniasis [9][10][11] . In particular, the use of cyclodextrin is highlighted [12][13][14] and has been applied in the pharmaceutical field primarily to increase solubility, chemical stability, and bioavailability.…”

mentioning

confidence: 99%

Use of pharmaceutical nanotechnology for the treatment of leishmaniasis

Marques

Júnior

Andrade

et al. 2019

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Leishmaniasis is a global public health concern. Currently available treatments are associated with considerable side effects. The use of nanotechnology has shown promise for improving efficacy and bioavailability and minimizing side effects. Methods: This study investigated available literature, including patents and scientific articles, to identify advances in the use of nanotechnology for the treatment of leishmaniasis. Results: Our findings revealed a stable number of patents and scientific articles published over the past five years. Conclusions: There is a need to intensify research on the use of nanotechnology for the treatment of leishmaniasis.

show abstract

Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani

Cited by 67 publications

References 36 publications

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis

Envisioning the Innovations in Nanomedicine to Combat Visceral Leishmaniasis: For Future Theranostic Application

Use of pharmaceutical nanotechnology for the treatment of leishmaniasis

Contact Info

Product

Resources

About